Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc.
Explore linked clinical trials.6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis | focal segmental glomerulosclerosis | Recruiting | Phase 2 / Phase 3 | 2026-09-02 | NCT07213960 | |
| A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Hemic and Lymphatic Diseases, Hemoglobinuria, Paroxysmal, anemia, bone marrow disorder, hematologic disorder, hemolytic anemia, myelodysplastic syndrome | Recruiting | Phase 2 | 2026-06-26 | NCT04901936 | |
| A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio | Geographic Atrophy Secondary to Age-related Macular Degeneration | Recruiting | Phase 2 | 2026-06-24 | NCT07215390 | |
| Lesion-tailored, Fundus-controlled Perimetry in Geographic Atrophy (GA). | Geographic Atrophy From Age-related Macular Degeneration | Recruiting | Not stated | 2026-06-17 | NCT07582042 | |
| A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Not stated | 2026-06-01 | NCT06161584 | |
| An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis | C3 glomerulonephritis, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, complement 3 glomerulopathy, glomerulonephritis, immune system disorder, kidney disorder, membranoproliferative glomerulonephritis, nephritis, urinary system disorder | Active, not recruiting | Phase 3 | 2026-04-02 | NCT05809531 |